Ralliant (NYSE:RAL) Price Target Lowered to $52.00 at Barclays

Ralliant (NYSE:RAL) had its price objective trimmed by Barclays from $60.00 to $52.00 in a research report report published on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms also recently commented on RAL. Truist Financial decreased their target price on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research note on Friday. Citigroup decreased their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday. Oppenheimer decreased their price target on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Royal Bank Of Canada decreased their price objective on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ralliant has a consensus rating of “Moderate Buy” and an average price target of $50.50.

Ralliant Trading Up 4.1%

Shares of RAL stock opened at $41.16 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $4.64 billion and a price-to-earnings ratio of 32.41. Ralliant has a 1 year low of $37.27 and a 1 year high of $57.02. The firm has a fifty day moving average price of $51.37 and a 200-day moving average price of $46.67.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is presently 15.75%.

Insider Buying and Selling

In related news, Director Kevin E. Bryant bought 1,250 shares of the business’s stock in a transaction on Friday, February 6th. The stock was acquired at an average cost of $39.97 per share, with a total value of $49,962.50. Following the purchase, the director directly owned 4,653 shares of the company’s stock, valued at $185,980.41. The trade was a 36.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Amir A. Kazmi purchased 2,545 shares of Ralliant stock in a transaction dated Friday, February 6th. The shares were bought at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the acquisition, the senior vice president owned 39,699 shares in the company, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Hedge Funds Weigh In On Ralliant

Several large investors have recently modified their holdings of RAL. Nordea Investment Management AB acquired a new stake in shares of Ralliant in the 2nd quarter valued at $29,477,000. Cullen Frost Bankers Inc. purchased a new position in Ralliant in the second quarter valued at $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Ralliant in the second quarter valued at $1,410,000. JPMorgan Chase & Co. acquired a new stake in Ralliant in the second quarter valued at $18,494,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Ralliant by 5,269.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock worth $14,000,000 after buying an additional 311,134 shares during the last quarter.

Key Stories Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Insiders increased holdings — SVP Amir Kazmi bought 2,545 shares (~$39.27 avg) and Director Kevin Bryant bought 1,250 shares; both filings signal management confidence and provide a supportive signal for investors. Insider Purchase Filings Insider Purchase Filings
• Positive Sentiment: Vertical Research upgraded RAL (reported by AmericanBankingNews), which can attract buyers and support the stock. Ralliant Upgraded at Vertical Research
• Neutral Sentiment: Barclays lowered its price target from $60 to $52 but kept an “overweight” rating — still implies upside (~26% from current levels) though the cut reduces near‑term bullishness. Barclays Price Target Cut
• Neutral Sentiment: Citigroup trimmed its price target to $51, a modest headwind for sentiment but still above current trading, indicating mixed analyst views. Citigroup Cuts Price Target
• Negative Sentiment: Multiple law firms (Kirby McInerney, Bragar Eagel & Squire, Kaplan Fox) have launched or publicized investigations into possible securities‑law violations at Ralliant — this is the biggest near‑term risk, as litigation, regulatory scrutiny or reputational damage can pressure the stock and increase volatility. Kirby McInerney Alert Bragar Eagel & Squire Alert Kaplan Fox Investigation

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.